Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Is setmelanotide the first true disease-targeted therapy for hypothalamic obesity?
Is setmelanotide redefining hypothalamic obesity treatment? Explore what Rhythm Pharmaceuticals, Inc.’s EU approval means for markets and growth.
Celcuity (NASDAQ: CELC) lines up July 17 FDA decision after Phase 3 VIKTORIA-1 win
Celcuity is up 1,058 percent in twelve months on Phase 3 wins. The harder question is whether July 17 FDA approval is already priced in.
Arvinas wins first FDA-approved PROTAC as ARVN stock tests investor patience
PROTAC drugs finally have FDA validation. Arvinas now faces the harder question: can VEPPANU become a commercial oncology asset?
Can the BACKBEAT trial validate a new category of device-driven hypertension therapy?
What does the BACKBEAT trial mean for Medtronic plc and Orchestra BioMed Holdings, Inc.? Discover the future of device-driven hypertension therapy.
Can an A3 adenosine receptor agonist change the treatment ceiling in advanced pancreatic cancer
Can Can-Fite BioPharma Ltd.’s namodenoson change pancreatic cancer outcomes? Explore what its Phase 2a data means for investors and oncology strategy.
Can cendifensine shift prescribing behavior in menopause management?
Can cendifensine reshape menopause prescribing trends? Discover how Noema Pharma AG’s strategy could influence treatment decisions.
Will ZEPHYR and IRIS data position MapLight Therapeutics, Inc. as a scalable CNS innovator?
MapLight Therapeutics nears dual CNS data readouts. Discover how ZEPHYR and IRIS could shape its strategy and market positioning.
Pharma M&A trends 2026: Why $1.3tn in firepower is meeting the steepest patent cliff in industry history
Big pharma has $1.3 trillion to deploy and $230 billion in revenue going off-patent by 2030. The 2026 deal map shows where the panic is real.
Can parallel CAR-T targeting finally solve relapse in multiple myeloma
Can dual-targeting CAR-T solve relapse in multiple myeloma? Explore how Tempest Therapeutics, Inc. is positioning TPST-2003 for next-gen impact.
A one-time lupus reset? Why CTA313 is forcing competitors to rethink strategy
Can CTA313 disrupt lupus markets with one-time remission? Explore how Imviva Biotech is reshaping autoimmune competition.